Development and patent progress of CDK4 / 6 inhibitors in more than 20 domestic companies

Two days ago, an article entitled "two nature confirmed that this kind of heavy-duty anticancer drugs can make cancer immunotherapy change" cattle ", wrote that in August this year, a study on nature said that the CDK4 / 6 inhibitor, a 2 billion" heavy-duty anticancer drug "sold in a year, was also immunotherapy, which immediately attracted strong attention Compared with the previously summarized Ido inhibitors (see: the global development and patent progress of IDO inhibitors), after that, Arnold pharmaceutical introduced new drugs with the same target of Suzhou guokuang The drugs that Ido inhibitors haven't been on the market are so popular Isn't it more popular that there are three kinds of CDK4 / 6 inhibitors on the market now! At present, the three CDK4 / 6 inhibitors on the market are from Pfizer, Novartis and Lilly Figure 1 Three listed CDK4 / 6 inhibitor drugs were found in the query patent, and domestic pharmaceutical companies have also carried out structural transformation around the listed drugs It is believed that the development success rate of the target will be greatly improved, but the clinical progress is relatively slow, and Hengrui medicine is currently in the leading position Table 1 development and patent progress of CDK4 / 6 inhibitors in China I believe that enterprises with PD-1 / PD-L1 can't help it In addition to Ido, they need a CDK4 / 6! What to do next depends on the negotiation between BD Attachment: Haihe pre clinical R & D pipeline Shanghai Xunhe pharmaceutical product line biebert pharmaceutical product line